Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Cash & Equivalents data on file, last reported at $78.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 35.5% year-over-year to $78.1 million in Q1 2026; TTM through Mar 2026 was $78.1 million, a 35.5% increase from a year earlier, with the FY2025 full-year figure at $52.6 million, down 7.32% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $78.1 million, up from $52.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RAPP reached as high as $513.0 million in Q3 2025 and fell as low as $39.3 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $129.3 million across 4 years, with a median of $76.2 million in 2024.
• Across the five-year window, Cash & Equivalents sank 75.34% in 2024 and surged 1204.88% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $70.2 million in 2023, then decreased by 19.05% to $56.8 million in 2024, then declined by 7.32% to $52.6 million in 2025, then surged by 48.27% to $78.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $78.1 million in Q1 2026, $52.6 million in Q4 2025, and $513.0 million in Q3 2025.